In 2015, we launched Nucala, the severe asthma, the first monoclonal antibody to target IL-5 ... Next slide, please. This chart illustrates the substantial margin progression we have continued ...

Vir Biotechnology’s sidelined hepatitis B candidate, designed to serve as a “functional cure,” has failed to achieve the ...

CNN: How is hepatitis A diagnosed and treated? Wen: The diagnosis requires a blood test, which looks for the presence of a particular antibody (hepatitis A virus IGM antibody) that identifies ...

In a very long-term follow-up cohort from childhood to adulthood in Taiwan, the scientists recruited 413 chronic HBV-infected patients who were followed from childhood to adulthood for a total of ...

The Coalition for Global Hepatitis Elimination's National Hepatitis Elimination Profiles assess the status of national data, ...

Vir is holding off on advancing the combination therapy to Phase III trials until it secures a development partner.

Vir Biotechnology (NASDAQ:VIR) on Friday announced 24-week post-end-of-treatment data from a mid-stage trial for tobevibart ...

The following abstracts will be presented as posters in the Viral Hepatitis B and D: New Therapies, Unapproved Therapies or Strategies session on May 8, 2025, from 8:30 am – 5:00 pm CET.

An antisense drug in development at GSK has shown further activity against hepatitis B virus (HBV) in a mid-stage trial, setting up a phase 3 assessment next year to see if it could offer a ...

Background Hepatitis B virus (HBV) is a common cause of viral ... all orders for HBsAg within a 17 month time period. Detailed chart review was performed to identify all patients who were ...